Clinical Trial Update: Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Window-of-opportunity neoadjuvant trial testing olaparib plus durvalumab in triple-negative or low ER+ breast cancer across Phase 1 and Phase 2; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Olaparib (Olaparib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Breast Neoplasms | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING